Therapeutic effect of interleukin 12 on mouse haemangiosarcomas is not associated with an increased anti-tumour cytotoxic T-lymphocyte activity
1998

Interleukin 12 and Its Effects on Tumor Growth in Mice

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): C Vizier, A Rosato, F Calderazzo, L Quintieri, P Fruscella, R Wainstok de Calmanovici, A Mantovani, A Vecchi, P Zanovello, D Collavol

Primary Institution: University of Padua

Hypothesis

Does interleukin 12 treatment enhance the immune response against H5V-induced tumors in mice?

Conclusion

Interleukin 12 treatment inhibits tumor growth but does not increase anti-tumor cytotoxic T-lymphocyte activity.

Supporting Evidence

  • IL-12 treatment significantly decreased the size of primary tumors.
  • High doses of IL-12 were required for effective tumor elimination.
  • Anti-IFN-y treatment abrogated the anti-tumor effect of IL-12.

Takeaway

This study found that a treatment called interleukin 12 can help stop tumors from growing in mice, but it doesn't make the immune system fight the tumors better.

Methodology

Mice were injected with H5V cells and treated with different doses of interleukin 12, followed by monitoring tumor growth and immune response.

Limitations

The study primarily focused on one type of tumor in mice, which may not fully represent human cancer responses.

Participant Demographics

C57BL/6 and BALB/C mice, female, 8-12 weeks old.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication